In 29 November to 2 December 2023, ZSHK Laboratories Limited. (hereinafter referred to as "ZSHK") wholly-owned subsidiary, Anling Biomed (Shenzhen) Co., Ltd. (hereinafter referred to as "Anling (Shenzhen)"), was invited to attend the 2023 Annual Meeting of Pharmacology and Toxicology and set up a booth at the event (Booth No.: E6), garnering widespread attention and praise from industry 
clients and top talent.

The conference focused on the theme of "Focusing on drug safety, introducing an international perspective, integrating innovative technologies, breaking through key bottlenecks, supporting innovative research and development, and promoting industrial development." It invited academicians, drug evaluation experts, directors or representatives of various specialized committees, leaders of the National Medical Products Administration (NMPA), GLP experts from the NMPA Drug Inspection and Verification Center, CDE experts, renowned scholars in the field of pharmacology and toxicology both domestically and internationally, as well as technical chief officers of listed companies and experts with extensive practical experience in pharmaceutical research and development to share and showcase the latest research findings and cutting-edge technological applications in the field of drug toxicology in China. Jin Yi, COO of ZSHK Laboratories Limited and General Manager of Anling (Shenzhen), gave a keynote presentation on "Risk-based Management of Quality Management Systems in Drug Development Laboratories."

The conference aimed to build a high-level academic exchange platform, strengthen industry collaboration and communication, and promote the sharing and mutual recognition of research data on the safety evaluation of new drugs. It will further enhance GLP standardization and standardization to promote the development of pharmacology and toxicology in China.